source
- ADCs Reshape the Future of Lung Cancer Care: From Second-Line Therapy to Earlier InterventionJudy Wang, MD, discusses how ADCs are transforming NSCLC treatment with improved responses, biomarker-driven care, and CNS activity.onclive · 2mo ago↗ source
- The OncFive: Top Oncology Articles for the Week of 5/3The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more.onclive · 2mo ago↗ source
- Dr Randall on Long-Term Responses and Functional Benefits With Pimicotinib in TGCTR. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.onclive · 2mo ago↗ source